ClinicalTrials.gg
CompletedNCT05572281Updated Mar 21, 2024

Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers

A Phase 1 interventional study of Tasimelteon Oral Capsule and Tasimelteon Oral Suspension in Healthy, sponsored by Vanda Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-21.

Sponsored by Vanda Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2022, 4 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a single center, two-period, randomized study to evaluate the bioequivalence of a single dose of tasimelteon capsule formulation relative to a single dose of liquid suspension formation in healthy volunteers.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and/or female participants between 18 to 55 years (inclusive).
  • Good health as determined by no deviations from normal in medical history, clinical laboratory determination, ECGs, and physical examinations conducted during the screening visit.
  • Participants with no clinically significant medical, psychiatric or sleep disorders as determined by the PI.

Exclusion criteria

Exclusion Criteria:

  • Participants with history of drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by the laboratory assays conducted during the screening or baseline evaluations.
  • Participants who suffered from significant physical illness (required hospitalization) in the 4-week period preceding baseline will be excluded.
  • Participants with history of smoking or use of tobacco products in the last 3 months.
  • Pregnant or nursing (lactating) women.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Sequence A

    tasimelteon liquid suspension formulation then tasimelteon capsule formulation

    Drug: Tasimelteon Oral Capsule · Drug: Tasimelteon Oral Suspension

  • Experimental
    Sequence B

    tasimelteon capsule formulation then tasimelteon liquid suspension formulation

    Drug: Tasimelteon Oral Capsule · Drug: Tasimelteon Oral Suspension

Interventions

06

What researchers measure

Primary outcomes

  1. Bioequivalence between tasimelteon capsule formulation relative to tasimelteon liquid suspension formulation

    as measured by plasma concentrations

    Time frame: 8 hours

  2. Assessment of Safety and Tolerability of the liquid suspension and capsule formulation of tasimelteon

    as measured by incidence of adverse events and clinically significant changes in laboratory values, ECG parameters, and vital signs

    Time frame: 7 days

07

Study locations

1 site
  • Vanda Investigational Site
    Springfield, Missouri 65802, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Jun 2022, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2022
First posted
Oct 7, 2022
StartActual
May 18, 2022
Primary completionActual
Jun 15, 2022
CompletionActual
Jun 15, 2022
Last update
Mar 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05572281
Responsible party
Sponsor
First posted
Oct 7, 2022
Start date
May 18, 2022
Primary completion
Jun 15, 2022
Completion
Jun 15, 2022
Last update
Mar 21, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tasimelteon

Start the discussion